HK1071304A1 - Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b - Google Patents

Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b

Info

Publication number
HK1071304A1
HK1071304A1 HK05104181.6A HK05104181A HK1071304A1 HK 1071304 A1 HK1071304 A1 HK 1071304A1 HK 05104181 A HK05104181 A HK 05104181A HK 1071304 A1 HK1071304 A1 HK 1071304A1
Authority
HK
Hong Kong
Prior art keywords
formation
preventing
complement pathway
pathway inhibitors
inhibitors
Prior art date
Application number
HK05104181.6A
Other languages
English (en)
Inventor
Michael S C M Fung
Cecily C Sun
Meisheng M Lu
William W Sun
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23214536&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1071304(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of HK1071304A1 publication Critical patent/HK1071304A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
HK05104181.6A 2001-08-17 2005-05-19 Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b HK1071304A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31313701P 2001-08-17 2001-08-17
PCT/US2002/026074 WO2003015819A1 (en) 2001-08-17 2002-08-17 Complement pathway inhibitors binding to c5 and c5a without preventing formation of c5b

Publications (1)

Publication Number Publication Date
HK1071304A1 true HK1071304A1 (en) 2005-07-15

Family

ID=23214536

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05104181.6A HK1071304A1 (en) 2001-08-17 2005-05-19 Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b

Country Status (14)

Country Link
US (6) US7432356B2 (ja)
EP (1) EP1425042B2 (ja)
JP (2) JP4958387B2 (ja)
CN (2) CN101387646B (ja)
AT (1) ATE360441T1 (ja)
AU (1) AU2002331601B2 (ja)
BR (1) BRPI0211953B8 (ja)
CA (1) CA2457461C (ja)
DE (1) DE60219801T3 (ja)
ES (1) ES2283594T5 (ja)
HK (1) HK1071304A1 (ja)
MX (2) MXPA04001301A (ja)
PT (1) PT1425042E (ja)
WO (1) WO2003015819A1 (ja)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE360441T1 (de) * 2001-08-17 2007-05-15 Tanox Inc Komplement-inhibitoren die an c5 und c5a binden ohne die bildung von c5b zu hemmen
US7361742B2 (en) 2002-12-02 2008-04-22 Resistentia Pharmaceuticals Ab Methods and materials for treating inflammatory conditions
EP1628530B8 (en) * 2003-05-15 2012-08-01 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
US20090028850A1 (en) 2004-05-14 2009-01-29 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
US20080076138A1 (en) 2005-03-02 2008-03-27 Astellas Pharma Inc. Novel Pd Marker for Histone Deacetylase Inhibitor
AU2006259057A1 (en) * 2005-06-14 2006-12-21 Cytos Biotechnology Ag Antigen conjugates and uses thereof
US20070292421A1 (en) * 2005-07-28 2007-12-20 Feinberg Bruce B Method for treating preeclampsia
CA2624393C (en) * 2005-11-04 2016-01-05 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
WO2007103134A2 (en) * 2006-03-02 2007-09-13 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
AU2007225044C1 (en) 2006-03-15 2018-03-29 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
EP2006381B1 (en) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Method for controlling blood pharmacokinetics of antibodies
RU2009110154A (ru) * 2006-08-22 2010-09-27 Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) АНТИТЕЛА ПРОТИВ C5aR С УЛУЧШЕННЫМИ СВОЙСТВАМИ
EP2913342A1 (en) 2006-09-05 2015-09-02 Alexion Pharmaceuticals, Inc. Compositions for use in the treatment of antibody mediated neuropathies
MY157948A (en) * 2006-11-02 2016-08-30 Genentech Inc Humanized anti-factor d antibodies
PL2202245T3 (pl) 2007-09-26 2017-02-28 Chugai Seiyaku Kabushiki Kaisha Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr
ES2563483T3 (es) 2008-04-11 2016-03-15 Chugai Seiyaku Kabushiki Kaisha Molécula de unión a antígeno capaz de unirse repetidamente a dos o más moléculas de antígeno
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
KR101680818B1 (ko) 2008-12-22 2016-11-29 케모센트릭스, 인크. Ｃ5ａｒ 길항제
EP2327725A1 (en) * 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
DK2563813T3 (en) 2010-04-30 2015-11-30 Alexion Pharma Inc Anti-c5a antibodies and methods of use of antibodies
WO2011163640A1 (en) 2010-06-24 2011-12-29 Chemocentryx, Inc. C5ar antagonists
US20140234340A1 (en) 2010-11-30 2014-08-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
EP2468295A1 (en) 2010-12-21 2012-06-27 Affiris AG Vaccines based on peptides of the complement protein C5a
DK2718322T3 (en) 2011-06-06 2018-12-03 Novo Nordisk As THERAPEUTIC ANTIBODIES
PL2817329T3 (pl) 2012-02-20 2019-07-31 Swedish Orphan Biovitrum Ab (Publ) Polipeptydy wiążące z c5 ludzkiego dopełniacza
US9133269B2 (en) 2012-08-24 2015-09-15 Anaptysbio, Inc. Humanized antibodies directed against complement protein C5
WO2014180961A1 (en) * 2013-05-08 2014-11-13 Novo Nordisk A/S Use of c5ar antagonists
US20140335546A1 (en) * 2013-05-10 2014-11-13 G J Carroll Pty Ltd Devices and Methods for Determining the Risk of Developing a Serious Infection
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
JP7138411B2 (ja) 2013-08-28 2022-09-16 アフィボディ・アーベー 変異した骨格を有する結合ポリペプチド
NZ718153A (en) * 2013-08-28 2022-05-27 Ipc Res Llc Stable polypeptides binding to human complement c5
NZ711451A (en) * 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
SG11201607740TA (en) * 2014-03-20 2016-10-28 Inflarx Gmbh Inhibitors of c5a for the treatment of viral pneumonia
CA2944712A1 (en) 2014-05-01 2015-11-05 Genentech, Inc. Anti-factor d antibody variants and uses thereof
SG11201702185UA (en) 2014-09-29 2017-04-27 Chemocentryx Inc PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS
KR20230044338A (ko) 2014-12-19 2023-04-03 추가이 세이야쿠 가부시키가이샤 항-c5 항체 및 그의 사용 방법
US20180016327A1 (en) 2015-01-22 2018-01-18 Chugai Seiyaku Kabushiki Kaisha A Combination of Two or More Anti-C5 Antibodies and Methods of Use
TW201718014A (zh) 2015-10-12 2017-06-01 諾華公司 C5抑制劑於移植相關微血管病之用途
CN108472382A (zh) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途
JP2018534930A (ja) 2015-10-30 2018-11-29 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体及びコンジュゲート
BR112018009067A8 (pt) 2015-12-18 2019-02-26 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
US20170202821A1 (en) 2016-01-14 2017-07-20 Chemocentryx, Inc. Method of treating c3 glomerulopathy
CN116751293A (zh) 2016-06-14 2023-09-15 瑞泽恩制药公司 抗c5抗体及其用途
CN115925922A (zh) 2016-06-17 2023-04-07 中外制药株式会社 抗-c5抗体及使用方法
CA3026050A1 (en) 2016-08-05 2018-02-08 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of il-8 related diseases
SG10201908697XA (en) 2017-01-31 2019-10-30 Chugai Pharmaceutical Co Ltd A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
WO2018165062A1 (en) * 2017-03-06 2018-09-13 The Trustees Of The University Of Pensylvania Anti-c5 antibodies and uses thereof
AU2018237300A1 (en) * 2017-03-23 2019-10-17 The Trustees Of The University Of Pennsylvania Anti-C5a antibodies and uses thereof
AU2018374469B2 (en) 2017-11-29 2022-06-16 F. Hoffmann-La Roche Ag Target interference suppressed anti-drug antibody assay
EP3724226A1 (en) 2017-12-13 2020-10-21 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
TWI704157B (zh) 2018-08-01 2020-09-11 日商中外製藥股份有限公司 在c5相關疾病之治療或預防中使用的醫藥組成物與治療或預防c5相關疾病的方法
CN114929273A (zh) 2019-07-31 2022-08-19 豪夫迈·罗氏有限公司 通过使用抗c5抗体可伐利单抗来治疗或预防c5相关疾病的剂量和施用方案
EP4003408A1 (en) 2019-07-31 2022-06-01 F. Hoffmann-La Roche AG Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab
TW202208427A (zh) 2020-05-06 2022-03-01 德商因夫萊亞斯有限公司 人源化抗ｃ５ａ抗體
AU2021294222A1 (en) 2020-06-16 2023-01-19 F. Hoffmann-La Roche Ag Method for determining the free antigen of an antibody in a sample
WO2023050233A1 (en) * 2021-09-29 2023-04-06 The Trustees Of The University Of Pennsylvania Humanized anti-c5a antibodies and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686100A (en) 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
ES2054667T3 (es) * 1986-04-28 1994-08-16 Cetus Oncology Corp Anticuerpos monoclonales contra c5a y des-arg74-c5a, su produccion y uso.
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5256766A (en) * 1991-02-19 1993-10-26 The Regents Of The University Of California Recombinant thrombin receptor and related pharmaceuticals
ES2236706T3 (es) * 1994-03-23 2005-07-16 Alexion Pharmaceuticals, Inc. Procedimiento para reducir las disfunciones de los sistemas inmunitario y hemostatico durante la circulacion extracorporal.
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5562904A (en) 1994-07-21 1996-10-08 Alexion Pharmaceuticals, Inc. Retroviral transduction of cells using soluble complement inhibitors
DE69534701T2 (de) * 1994-09-23 2006-10-19 Alexion Pharmaceuticals, Inc., Cheshire Verfahren zur behandlung von entzündlichen gelenkerkrankungen
US5572904A (en) * 1995-01-05 1996-11-12 Minculescu; Mihai C. Oscillation lever arm engine
US6673346B1 (en) * 1999-08-31 2004-01-06 The Regents Of The University Of Michigan Compositions and methods for the treatment of sepsis
ATE360441T1 (de) 2001-08-17 2007-05-15 Tanox Inc Komplement-inhibitoren die an c5 und c5a binden ohne die bildung von c5b zu hemmen

Also Published As

Publication number Publication date
MXPA04001301A (es) 2004-07-08
US20130230522A1 (en) 2013-09-05
BRPI0211953B1 (pt) 2019-05-28
JP2011051987A (ja) 2011-03-17
BRPI0211953B8 (pt) 2021-05-25
ATE360441T1 (de) 2007-05-15
ES2283594T5 (es) 2016-03-15
BR0211953A (pt) 2005-02-01
CN100391537C (zh) 2008-06-04
US8206716B2 (en) 2012-06-26
DE60219801T3 (de) 2016-06-16
PT1425042E (pt) 2007-07-11
US8372404B2 (en) 2013-02-12
JP5752374B2 (ja) 2015-07-22
CN1553813A (zh) 2004-12-08
DE60219801D1 (de) 2007-06-06
EP1425042A1 (en) 2004-06-09
AU2002331601B2 (en) 2006-04-13
US20150086572A1 (en) 2015-03-26
US7432356B2 (en) 2008-10-07
CA2457461A1 (en) 2003-02-27
US20030129187A1 (en) 2003-07-10
DE60219801T2 (de) 2008-01-17
EP1425042A4 (en) 2004-09-29
WO2003015819A1 (en) 2003-02-27
EP1425042B1 (en) 2007-04-25
CA2457461C (en) 2013-12-24
US20120301483A1 (en) 2012-11-29
CN101387646A (zh) 2009-03-18
JP2005508889A (ja) 2005-04-07
US20160200805A1 (en) 2016-07-14
US20080118508A1 (en) 2008-05-22
US8907072B2 (en) 2014-12-09
MX342385B (es) 2016-09-27
JP4958387B2 (ja) 2012-06-20
CN101387646B (zh) 2016-08-10
EP1425042B2 (en) 2016-02-10
ES2283594T3 (es) 2007-11-01

Similar Documents

Publication Publication Date Title
HK1071304A1 (en) Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b
WO2008140653A3 (en) Humaneered anti-factor b antibody
MA32928B1 (fr) Anticorps anti-cxcr4 et leur utilisation pour le traitement du cancer
GEP20104922B (en) Antibodies to m-csf
PH12015500248A1 (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
TN2010000210A1 (en) Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
NZ592786A (en) Methods and compositions for treating complement-associated disorders using eculizumab
MXPA05011886A (es) Metodos y composiciones para la prevencion y tratamiento de septicemia.
NO20092718L (no) Antagonist-anti-Notch 3-antistoffer og deres anvendelse i forebyggelsen og behandlingen av Notch 3-relaterte sykdommer
AU2006226733A8 (en) Antibodies against CD38 for treatment of multiple myeloma
WO2006125640A3 (en) Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38
WO2007042309A3 (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
TW200505481A (en) Compositions and methods for treating coagulation related disorders
MX2021000398A (es) Moleculas de anticuerpo que se unen a pd-l1 y cd137.
MA30876B1 (fr) Anticorps de la lymphotoxine-alpha
GEP20135826B (en) Novel antibodies used to treat cancer
AU2017236063A1 (en) Monoclonal antibodies against the active site of factor XI and uses thereof
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
EP1878441A3 (en) Complement pathway inhibitors binding to C5 and C5a without preventing the formation of C5b
SG148190A1 (en) Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer
MX2021008453A (es) Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos.
WO2002094194A3 (en) Compositions and methods for inhibiting metastasis
MX2022001411A (es) Metodos para tratar o prevenir canceres que implican la administracion de agentes receptores anti-ccr5.
DE602005025459D1 (de) Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
WO2019246176A8 (en) Anti-factor xii/xiia antibodies and uses thereof

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200817